The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES.
 
Andrew J. Armstrong
Honoraria - Astellas Scientific and Medical Affairs Inc
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Clovis Oncology; Dendreon; Merck; Pfizer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc
 
Taro Iguchi
Consulting or Advisory Role - Astellas Pharma; Bayer Yakuhin; Janssen
Speakers' Bureau - Astellas Pharma; Bayer Yakuhin; Janssen; Sanofi
Research Funding - Astellas Pharma; Bayer Yakuhin
 
Arun Azad
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); MedImmune (Inst); Merck Serono; Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Janssen; Merck Serono; Pfizer; Sanofi; Tolmar
 
Arnauld Villers
Consulting or Advisory Role - Astellas Pharma
Research Funding - Astellas Pharma (Inst); Janssen Oncology (Inst)
 
Boris Alekseev
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Janssen; Merck; MSD; Pfizer; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Janssen; Merck; MSD; Pfizer; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Janssen; Merck; MSD; Pfizer; Roche; Sanofi
Research Funding - Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Bristol-Myers Squibb; Eisai; ICON Clinical Research; Janssen; Merck; MSD; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Sanofi
 
Daniel P. Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Incyte; Ipsen; Janssen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Roche; Seagen; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Expert Testimony - Celgene; sanofi
 
Russell Zelig Szmulewitz
Honoraria - Astellas Pharma
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi
Research Funding - Abbvie; Astellas Pharma; Incyte; Janssen Oncology; Macrogenics
Patents, Royalties, Other Intellectual Property - Patent licensed by University of Chicago of which I am co-inventor to Corcept Therapeutics for combination AR/GR inhibition in prostate cancer
Travel, Accommodations, Expenses - Corcept Therapeutics
 
Antonio Alcaraz
No Relationships to Disclose
 
Neal D. Shore
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Sanofi; CG Oncology; CG Oncology; Clovis Oncology; Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; Foundation Medicine; Genesis Cancer Care; Genzyme; Genzyme; InVitae; Janssen Scientific Affairs; MDxHealth; Medivation/Astellas; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pacific Edge Biotechnology; Pfizer; Phosphorus; Propella Therapeutics; Sanofi; Sesen Bio; Tolmar; Urogen pharma
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Guardant Health; Janssen; Pfizer
Research Funding - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; Clovis Oncology; Dendreon; Exact Imaging; Ferring; Foundation Medicine; InVitae; Janssen; MDxHealth; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pfizer; Sanofi; Sesen Bio; Tolmar
 
Jeffrey Holzbeierlein
Consulting or Advisory Role - Basilea
Research Funding - MDxHealth (Inst)
(OPTIONAL) Uncompensated Relationships - Astellas Medivation
 
Francisco Gomez-Veiga
Honoraria - Abbvie; Astellas Pharma; AstraZeneca; Bayer; Ferring; GE Healthcare; GlaxoSmithKline; Ipsen; Janssen; Sanofi
Research Funding - Abbvie; Astellas Pharma; AstraZeneca
 
Brad Rosbrook
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Fabian Zohren
Employment - Pfizer
Stock and Other Ownership Interests - AlloVir (I); Pfizer
 
Gabriel P. Haas
Employment - Astellas Pharma
 
Georgia Gourgioti
Employment - Astellas Pharma
 
Nader N. El-Chaar
Employment - Astellas Pharma
 
Arnulf Stenzl
Consulting or Advisory Role - Alere; Bristol-Myers Squibb; Ferring; Ipsen; Janssen; Roche; Steba Biotech; Synergo
Research Funding - Amgen (Inst); Astellas Pharma; AstraZeneca; Bayer (Inst); Cepheid (Inst); GenomeDx (Inst); immatics (Inst); Janssen; Johnson & Johnson (Inst); Karl Storz (Inst); Medivation; Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - 2018/6579 Gene-expression signature for subtype and prognostic prediction of renal cell carcinoma; AT00/0001:C-Trap, implantable device to treat urinary incontinence; Patent A290/99 Implantable incontinence device
Expert Testimony - GBA Pharma
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; CureVac; Ferring; Ipsen; Janssen; Sanofi/Aventis